MedTrace Logo

Personalised Therapeutics @LUMC

NCT05508763 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-03-24

No results posted yet for this study

Summary

In PT@LUMC 2000 patients will be randomized between a PGx-guided dosing group and a standard of care group. The patients will be followed for one year in which they will be asked to report adverse drug reactions at one, three, six and twelve months.

Conditions

  • Adverse Drug Reaction

Interventions

GENETIC

Genetic test for 14 pharmacogenes

Genotyping with the Global Diversity Array-8 v1.0 BeadChip with enhanced PGx

Sponsors & Collaborators

  • bio.logis digital health GmbH

    collaborator UNKNOWN

  • Leiden University Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2026-02-28
Completion
2026-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05508763 on ClinicalTrials.gov